Gritstone bio Inc. (NASDAQ:GRTS) saw a downside of -3.47% to close Thursday at $10.42 after subtracting -$0.38 on the day. The 5-day average trading volume is 895,205 shares of the company’s common stock. It has gained $11.95 in the past week and touched a new high 1 time within the past 5 days. An average of 1,390,311 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,065,853.
GRTS’s 1-month performance is 17.39% or $0.86 on its low of $9.61 reached on 09/02/21. The company’s shares have touched a 52-week low of $2.54 and high of $35.20, with the stock’s rally to the 52-week high happening on 01/20/21. YTD, GRTS has achieved 174.11% or $6.47 and has reached a new high 8 times. However, the current price is down -70.38%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Sep 08, 23 days have gone by since the last insider trading activity for Gritstone bio Inc. (GRTS). Jones Erin (See Remarks) most recently sold 2,000 shares at $11.37 per share on Sep 08. This transaction cost the insider $22,748. See Remarks, Rousseau Raphael, sold 2,900 shares at a price of $9.00 on May 27. Then, on Jan 20, See Remarks Rousseau Raphael sold 10,000 shares at a price of $25.07 per share. This transaction amounted to $250,705.
Gritstone bio Inc. (GRTS) has a trailing price-to-earnings (P/E) ratio of 33.74 for the broader industry and 32.28 for the sector, meaning that investors are optimistic about the stock’s future prospects. GRTS stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 12.40 while the price-to-book (PB) in the most recent quarter is 2.98.
Gritstone bio Inc.’s quick ratio for the period ended June 29 was 8.20, with the current ratio over the same period at 8.20 meaning that GRTS stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00The trailing 12-month EBITDA margin is -2461.56%. The firm’s gross profit as reported stood at $110.05 million against revenue of $4.04 million.
The effectiveness of a company’s management is also important for investors when it comes to determining the potential profitability of the investment. Gritstone bio Inc.’s return on assets over the past 12 months stands at -34.60%. Return on investment over the past year is -63.60%, while its return on equity (ROE) trailing 12 months is -45.70%. In comparison, the average ROE for the broader industry over the past year is -36.91.
For the quarterly period ending June 29 this year, Gritstone bio Inc.’s cash and short-term investments amounted to $107.1 million against total debt of $22.35 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 82.75% to $2.84 million, while revenue of $39.69 million was -1297.54% off the previous quarter. Analysts expected GRTS to announce -$0.58 per share in earnings in its latest quarter, but it posted -$0.33, representing a 43.10% surprise. EBITDA for the quarter stood at more than -$23.33 million. GRTS stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 45.4 million, with total debt at $22.35 million. Shareholders hold equity totaling $49.45 million
Let’s look briefly at Gritstone bio Inc. (GRTS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 30 September was 40.65% to suggest the stock is trending Neutral, with historical volatility in this time period at 48.00%.
The stock’s 5-day moving average is $10.90, reflecting a -8.28% or -$0.94 change from its current price. GRTS is currently trading -3.61% above its 20-day SMA, +20.07% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +35.02% and +235.81% respectively.
Stochastic %K and %D was 4.83% and 7.70% and the average true range (ATR) pointed at 0.89. The RSI (14) points at 46.99%, while the 14-day stochastic is at 8.14% with the period’s ATR at 0.90. The stock’s 9-day MACD Oscillator is pointing at -0.60 and -0.97 on the 14-day charts.
In the most recent analyst report for Gritstone bio Inc. (NASDAQ: GRTS), Robert W. Baird downgraded it to an Underperform rating. They previously had an Outperform rating on the stock. Analysts offering their rating for GRTS stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate GRTS as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 3 have offered a “buy” rating.
What is GRTS’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $17.00 and a high of $35.00, with their median price target at $24.00. Looking at these predictions, the average price target given by analysts is for Gritstone bio Inc. (GRTS) stock is $25.33.